Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03646162 | Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer | PHASE2 | COMPLETED | 93 | — | — | Sep 14, 2018 | Oct 15, 2020 | Dec 3, 2021 | 24 | United States |
Percentage of change in frequency of moderate to severe hot flashes at 6 weeks
| Arm | Type | Description |
|---|---|---|
| Veru-944 10 mg | EXPERIMENTAL | Veru-944 10 mg daily |
| Veru-944 50 mg | EXPERIMENTAL | Veru-944 50 mg daily |
| Placebo | PLACEBO_COMPARATOR | Placebo daily |
| Name | Type | Description |
|---|---|---|
| Veru-944 | DRUG | Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT |
| Placebo | DRUG | Placebo |
Inclusion Criteria 1. Be over 18 years of age; 2. Be able to communicate effectively with the study personnel; 3. Have histologically confirmed prostate cancer; 4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months prior to randomization; 5. Be continued on an LHRH ...